Skip to main content
SpringerLink
Log in

The Role of Pharmacoeconomics in Health Policy and Management in Norway

  • Leading Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Drummond MF, Rutten F, Barena A, et al. Economic evaluation of pharmaceuticals: a European perspective. Pharmaceuticals 1993; 3: 173–86

    Google Scholar 

  2. Sosial department. Helsepolitikken mot ar 2000: nasjonal he1seplan. Stortingsmeldings nummer 41 (1987—88). Oslo: Sosial departementet. 1988

  3. Andersson F. Norway’s pivotal role in regulatory health economics and pharmaceutical cost containment: what can Other countries learn? Health Po1icy 1992; 21: 17–34

    Article  CAS  Google Scholar 

  4. Norges offentlige utredninger (NOU). Retningslinjer for prioriteringer innen norsk helsetjeneSle. NOU 1988:23. Oslo: UniversitelSforlaget AlS. 1987

  5. Lasana L, Werko L. International differences in drug regulation philosophy. Int J Technol Assess Health Care 1986: 2: 615–8

    Article  Google Scholar 

  6. Forskriftav 22 oktober om farmasoytiske spesialpreparater. Oslo: Sosialog helsedcpanementet. 1993

  7. Lovav 4 desember 1992 nummer 132 om legemidler med vidcreog om endringer i visse andre lousom folgeav Eosavtalen. Oslo: Sosialog helsedepartementet. 1992

  8. Lovav 20 juni 1964 nummer 5 om legemidler med videre. Oslo: Sosialog helsedepartementet. 1964

  9. Federation of Norwegian Pharmaceutical Manufacturers (NOMI) and Association of Norwegian Representatives of Foreign Pharmaceutical Manufacturers (NOMINO Re–Farm). Drugs and health 199211993. Oslo: NOMIINO Re–Farm, 1993

  10. Sosialog helsedepartementel. Interoepartemental aroidsgruppe for gjenmgang av prisog avansesystemer pllegemidler inorge. Oslo: Sosialog helsedepanementet. 1994

  11. Thorvik E, Amsnes J, Forsen L, et al. Cost and effects on longevity of lipid lowering drugs. Research report no. FI–1993. Oslo: National Institute of Public Health. 1993

    Google Scholar 

  12. Henr D. Economic anal~sis as an aid to suisidisation decisions. The development of Australian guidelines for pharmaceuticals. PharmacoEconomics 1992; 1: 54–67

    Article  Google Scholar 

  13. Mirchell A. The Australian perspective on the development of pharmacoeconomic guidelines. In: Schubert F, editor. Proceedings of the Canadian Collaborarive Worhhop on Pharmacoeconomics: 1993 Jun 21—22: Lc Chanteder. Sainte–Adtle, Quebec. Excerpta Medica Inc., 1993: 3–7

    Google Scholar 

  14. General discussion. In: Sakshaug S, Andrew M, Hjort PF, et al. editors. Drug utilization in Norway during the 1970, increase, inequalities, innovations. Oslo: Norwegian MedicinalDepot (Aktietrykkeriet). 1983: 231–44

  15. Sakshaug S, Lunde PK, Characteris tics of drug utilization induring the 1970 and 1980. In: Oydvin K, editor. Drug consumption in Norway 1981-1985. Oslo: Medicinal Depoe (Akrietrykkeriet). 1986: 19–27

    Google Scholar 

  16. Oydvin K. editor. Legemiddelforbruker i Norge 1986–1990. Oslo: Norsk Medisinaldepot. 1991

  17. Oydvin K. editor. Legemiddelforbruket i Norge 1988–92. Oslo: Norsk Medisinaldepot. 1993

  18. Norwegian Medicinal Depot. Annual report 1993. Oslo: Norwegian Medicinal Depot, 1994

  19. European Federation of Pharmaceutical Industries’ Associations (EFPIA). A brief guide to the EC rules governing medicines. Brussels: EFPIA. 1994

  20. Midlertidig forskrift av 17 descmber 1993 om prisfastsettelse av legemidler. Oslo: Sosial–og helsedepartementet, 1993

  21. Bloor KE, Maynard A. Cost–effective prescribing: the search for the holy grail? In: Drummond MF, Maynard A. editors. Purchasing and providing cost–effective health care. London: Churchill Livingstone. 1993: 198–216

  22. Finans-og tolldepartementet, Revidert nasjonalbudsjell, Stortingsmelding nummer 2 (1993–941). Oslo: Finans–og tolldepartementet. 1994

  23. Social-og helsedepanementet. Samarbeid og styring: mal og virkemidler for en hedre helsetjen este. Stoningsmeldingnummer 50 (1993-94). Oslo: Sosial–og helsedepanementer, 1994

  24. Sosial–og helsedepartementet. Stortingsproposisjon Hummer J (1994–95). Oslo: Social–og helsedepartementet. 1994

  25. Nordic Council on Medicines. Use of evaluations based on health economics in the administration ofmcdical products in the Nordic countries. Documentation from Nofdic WorkshopOn pharmacoeconomics; 1995 Mar 7–8 Stockholm. Uppsala: Nordic Council on Medicines. 1995

  26. Commonwealtll Deparrment of Health. Housing and Community Services, Guidelines, for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee: including submissions involving economic analyses. Canberra: Australian Government Publi shingService. 1992

  27. Ontario Ministry of Health. Ontario guideline s for economic analysis of pharmaceutical products. Toronto: Queen’s Printer for Ontario. 1994

  28. Canadian Coordinating Office on Health Technology Assessment. Guidelines for economic evaluation of pharmaceuticals Canada Ottawa: Canadian Coordinating Office OnHealth Technology Assessment. 1994

  29. Department of Health. Virginia Bouomley wdcomes pioneering guidelines for the economic evaluation of medicines press released. London: Department of Health. 1994 May 19

  30. Van Hoot B, Rutten F. Economic appraisal of health tednology in the European Community. In: Schubert F. editor. Proceedings of the Canadian Collaborative Workshop on Pharmacoeconomico; 1993 Jun 2 1–22: Lechanteder, Sainte, Adele,Quebec, Excerpta Medica Inc., 1993: 8–13

    Google Scholar 

  31. Drummond MF. Australian guidelines for cost–effectiveness studies of pharmaceulicals: the thin end of the boomerang? Pharmacoeconomics 1992; 1 Suppl. 1; 61–9

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre for Health Economics, Norwegian School of Management, Elias Smiths vei 15, 1300, Sandvika, Oslo, Norway

    Jan Grund & Hallstein Husbyn

Authors
  1. Jan Grund
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hallstein Husbyn
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Grund, J., Husbyn, H. The Role of Pharmacoeconomics in Health Policy and Management in Norway. Pharmacoeconomics 7, 475–483 (1995). https://doi.org/10.2165/00019053-199507060-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199507060-00002

Keywords

Search

Navigation